Current Hepatology Reports

, Volume 18, Issue 3, pp 357–362 | Cite as

Economic Analyses to Inform and Support Health Policy for Chronic Hepatitis B Treatment

  • Mehlika ToyEmail author
  • David W. Hutton
  • Samuel So
Hepatitis B (JK Lim, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Hepatitis B


Purpose of Review

Summarize insights into the economic impact of global hepatitis B treatment policies.

Recent Findings

With the highly effective antiviral treatment, entecavir and recently tenofovir, coming off patent, hepatitis B treatment is now very inexpensive and may save costs in the long run. In the USA alone, dramatic increases in screening and treatment would prevent between 80 and 100 thousand cases of cirrhosis, 50 and 60 thousand cases of liver cancer, and 80 to 100 thousand HBV-related deaths over the next 50 years.


Cost-effectiveness analyses can provide information in the form of what a proper course of action will cost, and what the benefits will be in terms of health impact. Since the sharp reduction in antiviral drug pricing, the focus should be on treating patients with generic antivirals to ensure that the chronic hepatitis B care and treatment efforts are highly cost-effective and even cost-saving.


Hepatitis B treatment Cost-effectiveness Health policy Economic analyses 


Compliance with Ethical Standards

Conflict of Interest

Mehlika Toy, David W. Hutton, and Samuel So each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• WHO. Global Hepatitis Report 2017. Geneva2017. Report No.: Licence: CC BY-NC-SA 3.0IGO.The first global hepatitis report, which provides a baseline for the drive towards elimination. The report contains global data on viral hepatitis B and C. Google Scholar
  2. 2.
    WHO. Global Health Sector Strategy on Viral Hepatitis 2016-2021. Towards Ending Viral Hepatitis 2016.Google Scholar
  3. 3.
    Organization WH. Viral hepatitis strategic information and modelling reference group: meeting report. Meeting report 14–16 June 2016, WHO headquarters, Geneva, Switzerland, vol. 2016. Switzerland: WHO headquarters Geneva.Google Scholar
  4. 4.
    Sicuri E, Evans DB, Tediosi F. Can economic analysis contribute to disease elimination and eradication? A Systematic Review. PLoS One. 2015;10(6):e0130603. Scholar
  5. 5.
    Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83. Scholar
  6. 6.
    European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98. Scholar
  7. 7.
    Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. WHO guidelines approved by the guidelines review committee. Geneva 2015.Google Scholar
  8. 8.
    • Hutin Y, Nasrullah M, Easterbrook P, Nguimfack BD, Burrone E, Averhoff F, et al. Access to treatment for hepatitis B virus infection - worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(28):773–7. Important review summarizing access to treatment of hepatitis B infection worldwide. CrossRefGoogle Scholar
  9. 9.
    Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.Google Scholar
  10. 10.
    Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med. 1990;113(2):147–54.CrossRefGoogle Scholar
  11. 11.
    Neumann PJ, Weinstein MC. Legislating against use of cost-effectiveness information. N Engl J Med. 2010;363(16):1495–7. Scholar
  12. 12.
    Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Mak. 1993;13(4):322–38. Scholar
  13. 13.
    Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013;13:181. Scholar
  14. 14.
    Goyal A, Murray JM. Cost-effectiveness of peg-interferon, interferon and oral nucleoside analogues in the treatment of chronic hepatitis B and D infections in China. Clin Drug Investig. 2016;36(8):637–48. Scholar
  15. 15.
    Toy M, Hutton DW, So SK. Cost-effectiveness and cost thresholds of generic and brand drugs in a National Chronic Hepatitis B Treatment Program in China. PLoS One. 2015;10(11):e0139876. Scholar
  16. 16.
    Toy M, Salomon JA, Jiang H, Gui H, Wang H, Wang J, et al. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai. China Hepatol. 2014;60(1):46–55. Scholar
  17. 17.
    Bermingham SL, Hughes R, Fenu E, Sawyer LM, Boxall E. P TK et al. cost-effectiveness analysis of alternative antiviral strategies for the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B in the United Kingdom. Value Health. 2015;18(6):800–9. Scholar
  18. 18.
    Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG. Cost-effectiveness of hepatitis B virus infection screening and treatment or vaccination in 6 high-risk populations in the United States. Open Forum Infect Dis. 2019;6(1):ofy353. Scholar
  19. 19.
    • Toy M, Hutton DW, So S. Population health and economic impacts of reaching chronic hepatitis B diagnosis and treatment targets in the US. Health Aff (Millwood). 2018;37(7):1033–40. A modeling study that quantifies screening and treatment to reach the WHO target in 2025 and 2030 in the US. CrossRefGoogle Scholar
  20. 20.
    Nayagam S, Conteh L, Sicuri E, Shimakawa Y, Suso P, Tamba S, et al. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in the Gambia: an economic modelling analysis. Lancet Glob Health. 2016;4(8):e568–78. Scholar
  21. 21.
    Kockaya G, Kose A, Yenilmez FB, Ozdemir O, Kucuksayrac E. Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey. Cost Eff Resour Alloc. 2015;13:21. Scholar
  22. 22.
    •• National Academies of Sciences E, and Medicine. A national strategy for the elimination of hepatitis B and C: phase two report. Washington 2017.Phase two report published by the National Academies that provides recommendations for achievement of US hepatitis B and C targets by 2030. Google Scholar
  23. 23.
    • Tordrup D, Hutin Y, Stenberg K, Lauer JA, Hutton DW, Toy M, et al. Additional resource needs for viral hepatitis elimination through universal health coverage: Projections in 67 low-income and middle-income countries, 2016–2030. Lancet Global Health. 2019; (In Press). A modeling study that calculates the cost to eliminate hepatitis B and C in 67 high prevalence countries if treatment were included as part of Universal Health Coverage. Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Asian Liver Centre, Department of SurgeryStanford University School of MedicinePalo AltoUSA
  2. 2.Department of Health Management and Policy, School of Public HealthMichigan UniversityAnn ArborUSA

Personalised recommendations